Memed is a technology company.
Memed has raised $86.5M across 6 funding rounds.
Key people at Memed.
Memed has raised $86.5M in total across 6 funding rounds.
Memed has raised $86.5M in total across 6 funding rounds.
Memed's investors include DNA Capital, George Godula, Amadeus Capital Partners, Endeavor Catalyst, Mathias Schilling, Kaszek Ventures, monashees, Mouro Capital, QED Investors, Qualcomm Ventures, Quona Capital, Redpoint eventures.
MeMed is a medtech company developing machine learning-based diagnostics that decode immune system signals to address infectious diseases and inflammatory disorders.[1][2] Its flagship product, MeMed BV, is an FDA-cleared, 15-minute point-of-care test that differentiates bacterial from viral infections with 97% accuracy, enabling precise antibiotic prescribing, reducing misuse, and improving patient outcomes.[2][3][5] The compact MeMed Key platform powers this by delivering rapid multiplexed protein measurements from blood samples.[1][2] MeMed serves clinicians, hospitals, and patients facing acute infections, solving the challenge of clinically indistinguishable infections that lead to inappropriate treatments and antibiotic resistance.[1][3]
Adopted by institutions like Maimonides Medical Center—the first in New York—MeMed BV streamlines workflows, supports stewardship, and enhances public health, with growing momentum from FDA approval in 2021 and clinical validation in trials.[5]
MeMed emerged from Israel as a diagnostics innovator, founded on molecular immunology and machine learning to interpret the body's immune response signals.[1][6] The idea stemmed from a core clinical dilemma: distinguishing bacterial from viral infections in patients with suspected infections, where traditional methods often fail due to indistinguishable symptoms.[1][2] Pivotal early traction came through rigorous clinical trials, including a multi-center study with over 1,000 participants that contributed to FDA clearance of MeMed BV in September 2021.[5] This validation propelled adoption, such as Maimonides Medical Center's landmark agreement, marking MeMed's shift from research to real-world impact in transforming infection management.[5]
MeMed rides the wave of precision diagnostics and AI-driven medtech, leveraging machine learning to unlock immune system insights amid rising antibiotic resistance—a crisis fueled by overuse.[2][3] Timing aligns with post-pandemic emphasis on rapid testing and stewardship, as seen in national action plans and FDA approvals.[5] Favorable market forces include demand for point-of-care tools that cut lab dependency, optimize workflows in overburdened hospitals, and counter emerging pathogens.[1][5] By influencing ecosystems through adoptions like Maimonides and scalable tech, MeMed advances bio-convergence, setting standards for immune-focused diagnostics in infectious disease management.[4][6]
MeMed's trajectory points to expansion beyond BV into severity assessment (MeMed Severity) and additional immune dilemmas, scaling its platform globally.[1] Trends like AI integration in healthcare and resistance pressures will accelerate adoption, potentially dominating point-of-care infectious diagnostics. Its influence may evolve by partnering with more health systems, influencing policy on stewardship, and pioneering next-gen tests—solidifying MeMed as a transformative force from immune signals to smarter care.[1][2]
Key people at Memed.
Memed has raised $86.5M across 6 funding rounds. Most recently, it raised $18.0M Series C in October 2021.
